From local player to global market leader and consolidator in the market of pharmaceutical compounding in only 25 years.

Fagron was founded in Rotterdam (the Netherlands) in 1990 by Ger van Jeveren, CEO of the Fagron Group. Through a continuous focus on innovation, quality and solution-oriented thinking, Ger van Jeveren brought market leadership in pharmaceutical compounding to Fagron in the Netherlands in just 7 years.

Ger van Jeveren continued to direct further development and international growth, with the result that Fagron is currently the global market leader and active in 30 countries in Europe, the Americas, Africa, the Middle East, Asia, and the Pacific. Fagron products are sold to 200,000 customers in over 60 countries around the world. Over 200 Fagron pharmacists are continually developing new, unique products and concepts to meet the growing worldwide need for tailor-made medication.

In 2007 Fagron opened its offices in Newcastle-upon-Tyne, and supplies raw materials, innovative concepts and small scale equipment to customers in the UK and Ireland in the pharmaceutical, veterinary, research, nutraceutical, cosmetic and herbal industries.

Market leadership provides major competitive advantages, such as the central procurement of raw materials, optimal utilisation of production facilities, and the international roll-out of successful and innovative products and concepts. With over 2,000 employees, Fagron expects to generate a turnover of at least € 400 million in 2014.

Fagron intends to further reinforce its worldwide market leadership based on an active buy-and-build strategy, starting up greenfields and robust organic growth.

Fagron mission and strategy
Fagron’s strategy is focused on the optimisation and innovation of pharmaceutical compounding.
As a R&D scientific pharmaceutical compounding company, Fagron wants to widen the therapeutic scope of the prescriber to enable tailor-made pharmaceutical care. Through its activities, Fagron supports the unique selling point of the pharmacist and improves the patient’s quality of life.